Clinical trials: Neuropathic Corneal Pain
Dry Eye, Neuropathic Pain
Effect of Trigeminal Nerve Stimulation on Corneal Nerves and Chronic Ocular Pain
Individuals with dry eye tend to present with ocular pain which persists despite the use of topical treatment. This could be secondary to somatosensory impairment attributable to neuropathic pain.
- Conditions
- Dry Eye, Neuropathic Pain, Eye Pain
- Trial name
- NCT04648085
- Testing
- Trigeminal Nerve Stimulation
- Where
- Mexico
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
Chronic Ocular Pain
Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
The study was designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (5 mg/mL and 15 mg/mL) in subjects with CICP persisting at least for 4 months after refractive or cataract surgery and…
- Trial name
- NCT04630158
- Testing
- SAF312
- Where
- 28 sites in United States, Japan and 1 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Corneal Pain, Chronic Pain
Effects of Transcranial Direct Current Stimulation (tDCS) in Chronic Corneal Pain
In this study the investigators aim to examine the effects of Transcranial Direct Current Stimulation (tDCS) on pain levels as well as the changes in cognitive (thought) processing in individuals with chronic pain of the cornea…
- Conditions
- Corneal Pain, Chronic Pain, Neuropathic Pain
- Trial name
- NCT01575002
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Spaulding Rehabilitation Hospital
Ocular Pain, Dry Eye
Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain
This study is designed to provide clinical data on how acoltremon ophthalmic solution 0.003% affects tear production and ocular symptoms in participants with tear deficiency and concurrent neuropathic corneal pain.
- Trial name
- AURORA (NCT07849803)
- Testing
- acoltremon ophthalmic solution 0.003%
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of South Florida
Corneal Disease, Neuropathy
NGF Treatment for Patients With Neuropathic Corneal Pain
This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic…
- Trial name
- NCT05700864
- Testing
- Cenegermin-Bkbj
- Where
- United States
- Sponsor
- Tufts Medical Center
Neuropathic Corneal Pain
Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).
This study is testing a new investigational study drug called Urcosimod Ophthalmic Solution for the treatment of Neuropathic Corneal Pain (NCP).
- Trial name
- NEPTUNE (NCT07838506)
- Testing
- Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Okyo Pharma Ltd
Neuropathic Corneal Pain
Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration
The goal of this study is to evaluate whether Quantum Molecular Resonance (QMR) treatment can effectively reduce eye pain and stimulate corneal nerve regeneration in patients with neuropathic corneal pain (NCP).
- Trial name
- NCT07174739
- Testing
- Quantum Molecular Resonance (QMR) Treatment
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore Eye Research Institute
Neuropathic Pain
The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
The primary objective of this study, in subjects with Neuropathic Corneal Pain, is to evaluate the efficacy and safety of OK-101 0.05% and 0.1% as compared to placebo instilled 4 times/day in subjects with neuropathic corneal…
- Trial name
- NCT06637527
- Testing
- OK-101 0.05%, OK-101 0.1%
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Okyo Pharma Ltd
Autoimmune Diseases, Dry Eye
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component.
- Conditions
- Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
- Trial name
- MNK (NCT06964269)
- Testing
- Acthar Gel 80 UNT/ML Injectable Solution
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Neuropathic Pain, Corneal Disease
Evaluation of the Clinical Efficacy and Mechanisms of Cord Plasma Eye Drops in the Treatment of Neuropathic Corneal Pain
The goal of this clinical trial is to investigate the efficacy and work of action of cord plasma eye drops in the treatment of neuropathic corneal pain (NCP).
- Trial name
- NCT07566806
- Testing
- Cord plasma eye drops
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Singapore Eye Research Institute
Dry Eye Syndromes, Corneal Disease
Prospective Study to Validate the Imaging Biomarker for NCP (R33)
The aim of this study is establish the reliability and clinical utility of microneuromas as identified via in vivo confocal microscopy as the diagnostic biomarker for NCP.
- Trial name
- NCT05653921
- Testing
- In vivo confocal microscopy (IVCM)
- Where
- 2 sites in United States
- Volunteers
- 438 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Cornea
Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain
This study is a prospective, interventional, open-label, single arm, non-randomized trial treating 30 patients with peripheral or mixed neuropathic corneal pain at their baseline exam and following 45 days and 90 days of daily…
- Trial name
- INSTANT (NCT03674892)
- Testing
- TrueTear™ intranasal neurostimulator (ITN)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Tufts Medical Center